“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”Investors are eyeing several biotech stocks for a potential rebound as market dynamics shift. Among them, Revance Therapeutics, Inc. (
NASDAQRVNC), Healthcare Triangle Inc.
NASDAQ: HCTINASDAQHCTI)
(NASDAQ: PRSONASDAQPRSO
, and Cardiol Therapeutics (NASDAQ: CRDLNASDAQ
) stand out as top investment opportunities with their latest strategic moves, analyst endorsements, and promising clinical advancements.
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and MoreNetworkNewsWire Editorial Coverage : Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer’s disease (“AD”) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (“FDA”) approvals of Leqembi and Kisunla — although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like peptide-1 (“GLP-1”) and phosphodiesterase 5 (“PDE5”) inhibitor drugs show promise in treating Alzheimer’s, with companies such as Annovis Bio Inc. (
NYSEANVS) ( profile ) leading the way with treatments ready for late-stage clinical trials. Beyond Alzheimer’s, the pharmaceutical industry is experiencing a surge of innovation across various disease areas. Major players, including Johnson & Johnson
NYSE: JNJNYSEJNJ)
(NYSE: NVSNYSENVS
, Merck & Co. Inc. (NYSE: MRKNYSE
) and GSK plc (NYSE: GSK
GSK) are at the forefront of medical innovation, tackling…
Novartis AG (NYSE: NVS) Highlighted for Surprising Price ActionNovartis AG (
NYSENVS) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 3.29% on the day to $97.47.
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal CancersPALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors, including the aging of the population, dietary choices, lifestyle changes, and the prevalence of Helicobacter pylori infection. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% during the forecast period 2024-2034. The report said: “The market will grow due to the rising incidence of gastric cancer, improvements in diagnostic technologies, emerging treatments and therapies, personalized medicine and precision medicine, government funding and initiatives, and technological advancements in surgery and minimally invasive procedures. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. For instance, in January 2024, Roche revealed encouraging findings from the Phase III RAINBOW research, which assessed the safety and effectiveness of ramucirumab when combined with chemotherapy to treat advanced stomach or gastroesophageal junction (GEJ) cancer.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (
NASDAQONCY) (TSX: ONC), Novartis AG
NYSE: NVSNYSENVS)
(NYSE: PFENYSEPFE
, GSK plc (NYSE: GSKNYSE
), Bristol Myers Squibb (NYSE: BMY
BMY).
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate AbusePALM BEACH, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as fentanyl, by incorporating aversive agents into transdermal patches. Abuse-deterrent opioid formulations (ADFs) are designed to make it more difficult to abuse opioids by making them less attractive or rewarding, or by increasing the difficulty of manipulating them. ADFs can help reduce the risk of adverse effects associated with snorting or injecting opioids, and may also help prevent medication errors. Active companies in the industry include: Nutriband Inc. (
NASDAQNTRB), Teva Pharmaceutical Industries Ltd.
NYSE: TEVANYSETEVA)
(NYSE: LLYNYSELLY
, Novartis AG (NYSE: NVSNYSE
), Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX
AMRX).
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (
NYSENVS), an innovative medicines company.
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for BiotechsPALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer cells removed during the biopsy are examined to check the presence of progesterone or estrogen receptor proteins. The hormones, i.e. estrogen and progesterone, encourage cancer growth when they bind to these receptors. If these receptors are present, cancers are classified as hormone receptor-positive or hormone receptor-negative (proteins). Breast cancer develops due to reasons, such as BRCA gene mutation and PIK3CA gene mutation etc. Ducts and lobules are the major components of a breast, and everything is held together by the connective tissue which surrounds it. Breast cancer develops where the ducts or lobules are located, and it can spread to other body parts via blood and lymph arteries. Breast cancer is metastasized when it spreads to other body regions. Advanced breast cancer is another word for metastatic breast cancer. Advanced breast cancer is defined in medical terms as breast cancer that has gone beyond the breast to other essential organs in the body, such as the bones, lungs, liver, or brain, to mention a few. Metastatic breast cancer usually develops months or years after a person has finished treatment for an early or locally advanced variety of breast cancer, such as stage I, II, or III. As a result, metastatic breast cancer is also known as distant recurrence. A report from Strategic Market Research predicted that the global metastatic breast cancer treatment market is expected to expand at a CAGR of 10.4% to reach $41.74 billion by 2030 during the period 2021-2030. The report said: “The most commonly prescribed treatments for metastatic breast cancer are chemotherapy and radiation therapy. Both of these treatments help to slow tumor growth. On the other hand, hormone therapy is the most successful treatment since it helps to limit the growth of cancer cells. The metastatic breast cancer treatment market trends like the introduction of more advanced technologies and rising demand for metastatic breast cancer therapies are some of the primary drivers driving the global market's growth.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (
NASDAQONCY) (TSX: ONC), Novartis AG
NYSE: NVSNYSENVS)
(NYSE: MRKNYSEMRK
, Pfizer Inc. (NYSE: PFENYSE
), Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD
GLMD).
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid TumorsVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and...
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment ModelAnnovis Bio (
NYSEANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data regarding buntanetap, its lead compound. According to the report, the date demonstrates the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease.
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ActivitiesPALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence, the Alzheimer's Disease Diagnostics And Therapeutics Market size is estimated at USD 7.70 billion in 2024, and is expected to reach USD 10.10 billion by 2029, growing at a CAGR of 5.57% during the forecast period (2024-2029). The report said: “The major factors driving the growth of the Alzheimer's disease diagnostics and therapeutics market are the increasing use of biomarkers in Alzheimer's diagnosis and drug development and the rising prevalence of Alzheimer's worldwide. For instance, in September 2023, a report by the WHO stated that about 55 million people around the world are living with dementia, and nearly 10 million cases are reported annually. WHO also said that Alzheimer's is the most common form of dementia and constitutes about 60%-70% of the total cases of dementia. Also, with the growing prevalence of Alzheimer's around the world, government and non-government entities are investing heavily in developing diagnostics and therapeutics for the disease, which may augment the market's growth.” Active biotech, pharma companies in the markets this week include: Annovis Bio Inc. (
NYSEANVS) (ANVS Profile), Merck & Co., Inc.
NYSE: MRKNYSEMRK)
(NASDAQ: SNYNASDAQSNY
, Johnson & Johnson (NYSE: JNJNYSE
), Novartis AG (NYSE: NVS
NVS).
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting–
Pharma Leader Beats on Earnings, But Shares FallNovartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug.
Leigh Burgess, CEO & Founder Bold Industries Group, Announces Pre-Sale of New Book: Be BOLD TodayBoston, MA - June 4, 2024 - Leigh Burgess, CEO & Founder of Bold Industries Group, is excited to announce the pre-sale of her book, Be BOLD Today: Unleash Your Potential, Master Your Mindset and Achieve Success. This inspirational guide is designed to empower individuals to take bold steps in their lives by embracing The BOLD Framework.
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and AcquisitionsActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) is increasingly regarded as a prime acquisition candidate amidst a surge of mergers and acquisitions (M&A) activity in the radiopharmaceutical sector. Recent deals, such as Novartis's acquisition of Mariana Oncology and AstraZeneca's purchase of Fusion Pharma, have underscored the vibrant investment interest in this niche of the oncology market.
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting –
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties –
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma FranchisePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company redefining...
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, SalesScinai Immunotherapeutics (
NASDAQSCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head of business development and sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as marketing and commercial excellence lead for cell and gene therapies for Central, Southern and Eastern Europe. “I am pleased to welcome Liat to Scinai,” said Amir Reichman, Scinai’s CEO. “Her pharmaceutical sales, marketing and leadership experience, in particular in Israel and Europe, align with our strategic decision to grow Scinai Bioservices CDMO into a trusted provider of drug development services, including for preclinical and clinical trials and GMP manufacturing for clinical supplies.”
